DRUG-FOOD INTERACTION

Yakovleva O. А., Konovalova N. V., Vitruk T. K., Krikus O. Yu., Kobirnichenko A. V.

LECTURES

Scentific article

Drug interactions is a section of clinical pharmacology that studies drug-druginteraction and a valuation of the relationship between drugs and food, drinks (drug-drug interaction/drug-nutrient) and herbal drug (drugherb interaction). The nutritional benefits of patients (hunger, fasting, popular diets, etc.) can have a different effect on the pharmacokinetics or pharmacodynamics of drugs. Most of the reported adverse reactions are related to changes in the bioavailability of drugs and, as a consequence, of the clinical efficacy of drugs. The working model for the classification of drug and food interactions is traditionally divided into pharmaceutical, pharmacokinetic and pharmacodynamic variants. Several mechanisms are proposed for the development of “fooddruginteraction”: physiological (changes in stomach motility, blood circulation stimulation and bile excretion, changes of pHor flora), physical and chemical (binding of drugs with food components) and biochemical (changes in the activity of enzymes, conveyors, modification of pharmacodynamic effects, etc.). The emergence of meaningful “food-drug interactions” can be expected (risk groups) in the elderly and children, patients with concomitant chronic poliorgan pathology, who take several drugs with a narrow therapeutic window and have an imbalance of nutrition. Most significant drug-food interactions have been documented during oral administrating of drugs. Food can change the degree and the rate of absorption, and thus can reduce the effectiveness of the prescribed therapy. The most significant variant of the pharmacokinetic interaction occurs at the level of biotransformation enzymes and/or protein carriers. For example, grapefruit bioflavonoids are potent inhibitors of CYP3A4 and CYP1A2. The consumption of grapefruit juice during the treatment with drugs of different groups can lead to the development of serious, potentially dangerous adverse reactions. Such changes can cause pomeranians, tangerines, grapes, mangoes, apples, spinach, tomatoes, cranberries, etc. in the clinic as well as in the experiment. Some products contain substances that can affect the same receptors or sites the same way as medicines, and therefore change the effect of drugs in one direction or another (agonists or antagonists). Long-term medication of prescriptive or non-prescriptive drugs can provoke subclinical or clinically significant deficiencies of certain nutrients. Medicines change the appetite, provoke nausea and vomiting, affect the taste buds, reduce the production of hydrochloric acid, alter the gastrointestinal motility or destroy its mucous membrane. The cases of adverse reactions to drugs associated with eating and/or dietary supplements have been documented and forced to draw attention to this problem at the state level. Different countries have published special recommendations on the rules for treatment with certain groups of drugs and the features of their interaction with beverages or food. Therefore, for the safe use of drugs it is important to know all the options for interaction of drugs, including the food components. This will ensure a personalized approach to each patient, and thus contribute to adherence of treatment. Collaboration of patients with doctors and pharmacists will help to reduce the risk of future dangerous variants of food and drug interactions.

drugs, food, interaction, pharmacokinetic, pharmacodynamics

1. Abdel-Rahman A, Anyangwe N, Carlacci L, Casper S, Danam RP, Enongene E, et al. The safety and regulation of natural products used as foods and food ingredients. Toxicol Sci. 2011;123:333-48.
2. Won CS, Oberlies NH, Paine MF. Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther. 2012;136:186-201.
3. Mason P. Important drug-nutrient interactions Proc Nutr Soc. 2010 Nov;69(4):551-7.
4. Boullata JI, Hudson ML. Drug-nutrient interactions: a broad view with implications for practise. Acad. Nutr. Diet. 2012;112,4:506-17.
5. Santos CA, Boullata JI. An approach to evaluating drug-nutrient interactions. Pharmacotherapy. 2005;25:1789-800.
6. Genser D. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab. 2008;52(Suppl 1):29-32.
7. Braun L. An introduction to: drug-nutrient interactions. IMER Meet March, Monash Univ. 2012:1-41.
8. Alshammari TM. Drug safety: the concept, inception and its importance in patients’ health. Saudi Pharmaceutical Journal. 2016;24:405-12.
9. Schmidt LE, Dalholf K. Food-drug interaction. Drugs. 2002;62(10):1481-502.
10. Ayo JA, Aguv H, Madaki I. Food and drug interactions: its side effects. Nutr Food Scio. 2005;35(4):243-52.
11.  Boullata JI, Armenti VT. Handbook of Drug-Nutrient Interactions. Front Cover. Springer Science & Business Media. Science. 2010. Mar 17. 824 p.
12. Singh BN, Mahora BK. Effects of food on the clinical pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2004;43:1127-56.
13. Pons ST, Boyer A, Lamblin G, Chennel Ph, Chatenet F-Th, Nicolas C, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis С. Br J Clin Pharmacol. 2017;83(2):269-93.
14. Viktorov OP. Pobichni reakcii pri medichnomu zastosuvanni likiv v Ukraini: vikoviy aspekn. Racionalna pharmacotherapiy. 2010;3(16):11-8. [in Ukrainian].
15. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24:1670-751.
16. Vaquero MP, Sánchez Muniz FJ, Jiménez Redondo S, Prats Oliván P, Higueras FJ, Bastida S. Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins. Nutr Hosp. 2010 Mar Apr;25(2):193-206.
17. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet. 2003;42:969-84.
18. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 «pie». Drug Metab Dispos. 2006;34:880-6.
19. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol. 2011;7:267-86.
20. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81:362-70.
21. Rodriguez-Fragoso L, Martinez-Arismendi JL, Orozco-Bustos D, Reyes-Esparza J, Torres E, Burchiel SW. Potential risks resulting from fruit/ vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters. J Food Sci. 2011;76:112-24.
22. Lee JW, Morris JK, Wald NJ. Grapefruit juice and statins. Am J Med. 2016;129:26-9.
23. Bailey DG, Dresser G, Arnold MO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185:309-16.
24. Fragoso RL, Esparza RJ. Fruit/vegetable-drug interactions: effects on drug metabolizing enzymes and drug transporters. Intech. 2013:1-34.
25. Srinivas NR. Cranberry juice ingestion and clinical drug-drug interaction potentials: review of case studies and perspectives. J. Pharm. Pharm. Sci. 2013;16:289-303.
26. Mohn E, Kern H, Saltzman E, Mitmesser S, McKay D. Evidence of drug-nutrient interactions with chronic use of commonly prescribed medications: an update. Pharmaceutics. 2018;10(1):36-81.
27. Karadima V, Kraniiotou C, Bellos G, Tsangaris GT. Drug-nutrient interactios: food for thought and thought for drug action. EPMA J. 2016;7:1-5. 28. de Boer A, van Hunsel F, Bast A. Adverse food-drug interactions. Regul Toxicol Pharmacol. 2015 Dec;73(3):859-65.

«Bulletin of problems biology and medicine» Issue 1 Part 1 (148), 2019 year, 10-14 pages, index UDK 615.363+613.2

10.29254/2077-4214-2019-1-1-148-10-14